NeuroVive Redirects Research Resources From Asian Subsidiary to Parent
NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that its Taiwan-based subsidiary’s research resources and activities will be redirected to the parent company NeuroVive Pharmaceutical AB.
News story posted on 2017-01-25T02:40:00